The long term goal of this study is to define new therapeutic targets of osteoclast related bone diseases, such as osteoporosis and tumor bone metastasis. The immediate goal of this study is to understand the mechanisms underlying the transcription factors that regulate osteoclast lineage commitment and differentiation. The critical need for the treatments of osteoclast related bone diseases has been exacerbated by the recent discovery that the negative effects (e.g., jaw osteonecrosis) of currently used osteoclast inhibitors may outweigh the benefits. The mechanism underlying transcription factors that specify osteoclast lineage commitment, differentiation, and function remains unclear. It is also necessary to clarify why M-CSF alone induces precursors to differentiate into macrophages, while both M-CSF and RANKL induce precursors to differentiate into osteoclasts. Further study is needed to address these biological questions. As a step towards understanding the transcription factors which modulate osteoclast gene (e.g., cathepsin K) expression and osteoclast differentiation, we are characterizing the cathepsin K critical cis-regulatory elements (CCREs). We found a CCAAT/enhancer-binding protein ? (C/EBP?) binding site as a CCRE and confirmed C/EBP? as its trans-regulatory factor as the CCRE binding protein (CCREBP). Our Preliminary Studies further demonstrated that only the combined stimulation of M-CSF and RANKL will induce C/EBP? high expression;that in vitro C/EBP? knockdown blocks osteoclast differentiation and overexpression increase osteoclast formation;and that C/EBP? knockout in mice (C/EBP?-/-) impaired osteoclastogenesis and resulted in an osteopetrotic phenotype. Based on our Preliminary Study data, we hypothesize that C/EBP? is the key osteoclastogenesis transcription factor that regulates osteoclast lineage commitment and differentiation in the M-CSF and RANKL-dependent signaling pathway(s) through interactions with its heterodimerization partners and regulation of osteoclast genes. We will test this hypothesis through four specific aims:
in Aim 1, we will investigate the role of C/EBP? in osteoclast differentiation by characterizing the phenotypes and pathomechanism of C/EBP? null mutation mice (C/EBP?-/-) compared with C/EBP?+/+ mice.
In Aim 2, we will reveal the function of C/EBP? at various stages of osteoclast differentiation through characterization of the phenotypes and pathomechanism of three C/EBP? conditional knockout mouse models.
In Aim 3, we will define in vitro the roles of C/EBP? at different stages of osteoclast differentiation using RNAi knockdown as a loss-of-function study and retrovirus overexpression as a gain-of-function study.
In Aim 4, we dissect the mechanism of C/EBP? interactions that confers osteoclastic specificity by characterizing C/EBP? heterodimerization partners, downstream genes and their functions. This study will not only improve our understanding of the role of transcription factors in normal osteoclast differentiation and function and in osteolytic diseases (e.g., osteoporosis and bone metastases), but it will also facilitate the design of novel approaches for their precise treatment using drug or somatic gene therapy.
This study endeavors to increase our understanding of the mechanisms underlying the transcription factors that regulate osteoclast lineage commitment and differentiation. In so doing, this study will elucidate how transcription factors specify osteoclast cell lineage commitment and differentiation. This study will not only improve our understanding of the role of transcription factors in normal osteoclast differentiation and functio and in osteolytic diseases (e.g., osteoporosis and bone metastases), but it will also facilitate th design of novel approaches for their precise treatment using drug or somatic gene therapy.
|McConnell, Matthew; Feng, Shengmei; Chen, Wei et al. (2017) Osteoclast proton pump regulator Atp6v1c1 enhances breast cancer growth by activating the mTORC1 pathway and bone metastasis by increasing V-ATPase activity. Oncotarget 8:47675-47690|
|Wu, Mengrui; Wang, Yiping; Shao, Jian-Zhong et al. (2017) Cbf? governs osteoblast-adipocyte lineage commitment through enhancing ?-catenin signaling and suppressing adipogenesis gene expression. Proc Natl Acad Sci U S A 114:10119-10124|
|Jules, Joel; Chen, Wei; Feng, Xu et al. (2016) CCAAT/Enhancer-binding Protein ? (C/EBP?) Is Important for Osteoclast Differentiation and Activity. J Biol Chem 291:16390-403|
|Wu, Mengrui; Chen, Guiqian; Li, Yi-Ping (2016) TGF-? and BMP signaling in osteoblast, skeletal development, and bone formation, homeostasis and disease. Bone Res 4:16009|
|Li, Sheng; Hao, Liang; Wang, Lin et al. (2015) Targeting Atp6v1c1 Prevents Inflammation and Bone Erosion Caused by Periodontitis and Reveals Its Critical Function in Osteoimmunology. PLoS One 10:e0134903|
|Jules, Joel; Yang, Shuying; Chen, Wei et al. (2015) Role of Regulators of G Protein Signaling Proteins in Bone Physiology and Pathophysiology. Prog Mol Biol Transl Sci 133:47-75|
|Hao, Liang; Zhu, Guochun; Lu, Yun et al. (2015) Deficiency of cathepsin K prevents inflammation and bone erosion in rheumatoid arthritis and periodontitis and reveals its shared osteoimmune role. FEBS Lett 589:1331-1339|
|Zhu, Zheng; Chen, Wei; Hao, Liang et al. (2015) Ac45 silencing mediated by AAV-sh-Ac45-RNAi prevents both bone loss and inflammation caused by periodontitis. J Clin Periodontol 42:599-608|
|Wang, Yiping; Li, Yi-Ping; Paulson, Christie et al. (2014) Wnt and the Wnt signaling pathway in bone development and disease. Front Biosci (Landmark Ed) 19:379-407|
|Tian, Fei; Wu, Mengrui; Deng, Lianfu et al. (2014) Core binding factor beta (Cbf?) controls the balance of chondrocyte proliferation and differentiation by upregulating Indian hedgehog (Ihh) expression and inhibiting parathyroid hormone-related protein receptor (PPR) expression in postnatal cartilage and J Bone Miner Res 29:1564-1574|
Showing the most recent 10 out of 45 publications